home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.660 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 26, 2023

Via Benzinga

Coherus BioSciences Stock Is Soaring After-Hours - Here's Why ↗

December 26, 2023

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher in Tuesday's after-hours session following the company's announcement of the U.S.

Via Benzinga

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

December 26, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street ↗

December 24, 2023

These two biotech stocks could be poised for a trend reversal.

Via The Motley Fool

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

December 11, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

What 6 Analyst Ratings Have To Say About Coherus BioSciences ↗

November 28, 2023

Via Benzinga

Analyst Ratings for Coherus BioSciences ↗

November 08, 2023

Via Benzinga

Coherus BioSciences Announces CFO Transition Plans

December 07, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

December 06, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗

December 02, 2023

LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...

Via Talk Markets

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical

November 28, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus Biosciences Stock Dropped Today ↗

November 07, 2023

Coherus missed estimates for the third quarter and lowered its full-year outlook.

Via The Motley Fool

Why Coherus BioSciences Was Plummeting This Week ↗

November 10, 2023

The company has been punished harshly for a worse-than-expected quarter.

Via The Motley Fool

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 07, 2023

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 07, 2023

Via Benzinga

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Coherus BioSciences's Earnings: A Preview ↗

November 03, 2023

Via Benzinga

Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗

November 07, 2023

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 07, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 07, 2023

It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.

Via InvestorPlace

Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 07, 2023

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 06, 2023

Via Benzinga

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

November 06, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗

November 04, 2023

Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have...

Via Talk Markets

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

November 03, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences to Participate at Upcoming November Investor Conferences

November 02, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

BP, V.F. Corporation, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 31, 2023

U.S. stock futures traded mostly higher this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

October 30, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus BioSciences Stock Soared Today ↗

October 30, 2023

Coherus and Junshi Biosciences announced the long-awaited FDA approval of NPC drug Loqtorzi. Here's what investors need to know.

Via The Motley Fool

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com